about
TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cellsCloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2)Growth inhibitory retinoid effects after recruitment of retinoid X receptor beta to the retinoic acid receptor beta promoterThe estrogen-responsive B box protein is a novel regulator of the retinoid signalTranslational development of difluoromethylornithine (DFMO) for the treatment of neuroblastomaTherapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemiaMRP1 gene expression level regulates the death and differentiation response of neuroblastoma cellsThe histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.Cell-based methods for the identification of MYC-inhibitory small moleculesImproving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual diseaseABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.The p53 pathway and its inactivation in neuroblastoma.An unexpected role for caspase-2 in neuroblastoma.High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.Molecular profiling of childhood cancer: Biomarkers and novel therapiesActivation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.The retinoid anticancer signal: mechanisms of target gene regulation.The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression.ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells.Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteeMechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growthMYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.ABC transporters as mediators of drug resistance and contributors to cancer cell biology.Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation.Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma.Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.
P50
Q24297046-09FE7B0C-A2F6-4D46-83AD-1D5D459BFD57Q24298256-721D1D81-AC20-4A98-BC8D-C421B5A09FC0Q24302705-DAA798E8-7827-4FEE-BC4A-C74DB141B057Q24319942-5B589068-81AF-4C1E-90F4-B3DA153A63E1Q26770306-73A02453-D401-4C1E-90A3-C3094BC9ECD8Q27853237-461FE675-F5B3-49C0-AAB8-3906A46AF919Q28240130-C8F9559F-08AA-4BE8-9E92-45194252F342Q28364926-A9F0D16C-9D77-436A-9AB8-A0095E4F7540Q33688385-52987008-18AC-48B4-9E3A-70096C126D3DQ34100931-7BC26705-74B0-4A30-9561-927DDD9403B6Q34398691-E5129D10-D5B1-4254-82B5-E9A4E14921FBQ34482630-E0390E90-78AD-4686-997E-3DF7E5B2BC37Q34519715-69161CB0-9D1F-42B4-9B81-7C84771B2EB4Q34978492-9E032F74-446B-4458-B3F2-BABD2D9A70B3Q35022780-610D572B-C0C7-47DE-9F12-1BAC2092774AQ35166695-7102AADD-7742-4FFA-AAED-4D028660003CQ35184948-8168CEB7-389D-4993-9BAE-8B37C32F4861Q35679550-117F565D-9389-4DEA-BA27-7032D3287595Q35931599-0F309BEE-0C86-4D58-8607-CCA6BD18C22BQ36021061-FF141280-737A-4B23-8E76-1D2892A8A711Q36056038-3BD028F3-BB48-4B7F-8480-47D677A43007Q36250783-2D464AF2-4554-4F83-B903-CFECBFE0DAEBQ36276954-7EC67A5A-3B21-4FC8-82D7-C8DC85A91C09Q36615158-964C98B7-6DAB-498C-B978-F107149C51A6Q36962372-2D201693-1615-4B96-BD60-6E65794396A8Q37080926-751DDA0B-C594-41F1-8B7D-D7EBE8BA5FFCQ37164456-9B0B30E0-5E36-49B0-8860-04C0F91700DDQ37222603-C248F8E6-A03C-4855-B5CF-0EDFE003C751Q37494210-32E58672-87EA-4478-83DF-AA6B7FEE2958Q37565172-234C1594-7401-40EA-9463-E6F5968F9965Q37688166-0AC4FD74-C625-4F82-BB77-6A1633652DB7Q38727375-440CFEAF-9829-4D44-B28B-052B62D6DE67Q38834784-74AAF702-4FCA-4F71-B4AA-44C5766C04DAQ38876333-AA19F7B1-91D4-4AD0-B5EB-576511B638DDQ38980150-B749BB08-89DF-42B1-B98A-B818D727AB0CQ39041489-F37D87FC-F97B-49AA-A3CF-A05CE4B63A2BQ39228542-8D30E8B7-27A1-4034-8E6D-23453C4595B7Q39294214-C8F1F6DB-0B09-4F0A-BD01-25ADBC0ECA01Q39498028-D7026B97-1975-47EF-97BE-84BCDCE6C241Q39793773-1C70DC8D-79D3-489F-8ED8-B12C7BF0CCB4
P50
description
researcher
@en
name
M Haber
@ast
M Haber
@en
M Haber
@nl
type
label
M Haber
@ast
M Haber
@en
M Haber
@nl
prefLabel
M Haber
@ast
M Haber
@en
M Haber
@nl
P106
P31
P496
0000-0003-2036-8817